Send to

Choose Destination
Diabetologia. 2016 Jan;59(1):87-91. doi: 10.1007/s00125-015-3790-6. Epub 2015 Nov 7.

Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries.

Author information

Pediatric Endocrinology, Children's Diabetes Program, Yale School of Medicine, New Haven, CT, USA.
ZIBMT, Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany; affiliated with the German Center for Diabetes Research (DZD).
General Paediatrics and Diabetes, Leeds Children's Hospital, Leeds, UK.
Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL, 33647, USA.
Department of Paediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Department of Paediatric Endocrinology and Diabetes, Royal London Children's Hospital, Barts Health NHS Trust, London, UK.
Barbara Davis Center for Childhood Diabetes, Aurora, CO, USA.
Department of Endocrinology and Diabetology, University of Leipzig, Hospital for Children and Adolescents, Leipzig, Germany.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL, 33647, USA.
Paediatric Endocrinology and Diabetes, Children's Hospital for Wales, Cardiff, UK.



While the use of insulin pumps in paediatrics has expanded dramatically, there is still considerable variability among countries in the use of pump technology. The present study sought to describe differences in metabolic control and pump use in young people with type 1 diabetes using data collected in three multicentre registries.


Data for the years 2011 and 2012 from 54,410 children and adolescents were collected from the Prospective Diabetes Follow-up Registry (DPV; n = 26,198), T1D Exchange (T1DX; n = 13,755) and the National Paediatric Diabetes Audit (NPDA; n = 14,457). The modality of insulin delivery, based on age, sex and ethnic minority status, and the impact of pump use on HbA1c levels were compared.


The overall mean HbA1c level was higher in the NPDA (8.9 ± 1.6% [74 ± 17.5 mmol/mol]) than in the DPV (8.0 ± 1.6% [64 ± 17.0 mmol/mol], p < 0.001) and T1DX (8.3 ± 1.4% [68 ± 15.4 mmol/mol], p < 0.001). Conversely, pump use was much lower in the NPDA (14%) than in the DPV (41%, p < 0.001) and T1DX (47%, p < 0.001). In a pooled analysis, pump use was associated with a lower mean HbA1c (pump: 8.0 ± 1.2% [64 ± 13.3 mmol/mol] vs injection: 8.5 ± 1.7% [69 ± 18.7 mmol/mol], p < 0.001). In all three registries, those with an ethnic minority status were less likely to be treated with a pump (p < 0.001) and boys were treated with a pump less often compared with girls (p < 0.001).


Despite similar clinical characteristics and proportion of minority participants, substantial differences in metabolic control exist across the three large transatlantic registries of paediatric patients with type 1 diabetes, which appears to be due in part to the frequency of insulin pump therapy.


Clinical outcomes; Continuous subcutaneous insulin infusion; DPV; Insulin pumps; National Paediatric Diabetes Audit; T1D Exchange clinic registry; Treatment modalities; Type 1 diabetes

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center